Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.86 |
| ▸ | SLCO1B3 | Q9NPD5 | 4/20 | 0.86 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.86 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.86 |
| ▸ | SLCO2B1 | O94956 | 3/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.86 |
| ▸ | HPGD | P15428 | 2/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.86 |
| ▸ | MEN1 | O00255 | 2/20 | 0.86 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.86 |
| ▸ | GAA | P10253 | 2/20 | 0.86 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.86 |
| ▸ | F2 | P00734 | 1/20 | 0.86 |
| ▸ | PLAU | P00749 | 1/20 | 0.86 |
| ▸ | TP53 | P04637 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosilybin A SCHEMBL972938 | 0.93 | CYP3A4 (1.00) | MAPTCYP2C9SLCO1B3SLCO1B1CYP3A4 | |
| Silibinin SCHEMBL678427 | 0.93 | CYP3A4 (1.00) | MAPTCYP2C9SLCO1B3SLCO1B1CYP3A4 | |
| Silibinin SCHEMBL19194836 | 0.93 | CYP3A4 (1.00) | MAPTCYP2C9SLCO1B3SLCO1B1CYP3A4 | |
| Silibinin SCHEMBL22993978 | 0.93 | CYP3A4 (1.00) | MAPTCYP2C9SLCO1B3SLCO1B1CYP3A4 | |
| Silybin A SCHEMBL324884 | 0.93 | CYP3A4 (1.00) | MAPTCYP2C9SLCO1B3SLCO1B1CYP3A4 | |
| Silibinin SCHEMBL24236664 | 0.93 | CYP3A4 (1.00) | MAPTCYP2C9SLCO1B3SLCO1B1CYP3A4 | |
| Silybin B SCHEMBL751461 | 0.93 | CYP3A4 (1.00) | MAPTCYP2C9SLCO1B3SLCO1B1CYP3A4 | |
| Silybin A SCHEMBL23466786 | 0.93 | CYP3A4 (1.00) | MAPTCYP2C9SLCO1B3SLCO1B1CYP3A4 | |
| Silibinin SCHEMBL22398934 | 0.93 | CYP3A4 (1.00) | MAPTCYP2C9SLCO1B3SLCO1B1CYP3A4 | |
| Isosilybin A SCHEMBL18089487 | 0.93 | CYP3A4 (1.00) | MAPTCYP2C9SLCO1B3SLCO1B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392326-B9 | Silibinin component for the treatment of hepatitis | MADAUS GMBH (DE) | 2018-09-05 | — | — | EP | disclosed |
| EP-2392326-B1 | Silibinin component for the treatment of hepatitis | MADAUS GMBH (DE) | 2018-01-24 | — | — | EP | disclosed |
| EP-2430017-B1 | A method for preparing AMORPHOUS SILIBININ | MADAUS GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-9248115-B2 | Silibinin component for the treatment of hepatitis | MADAUS GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| US-8614341-B2 | Amorphous silibinin for the treatment of viral hepatitis | EUROMED S.A. (ES) | 2013-12-24 | — | — | US | disclosed |
| US-20130236420-A1 | SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS | MADAUS GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| US-20120108825-A1 | AMORPHOUS SILIBININ FOR THE TREATMENT OF VIRAL HEPATITIS | EUROMED S.A. (ES) | 2012-05-03 | — | — | US | disclosed |
| WO-2011044638-A1 | METHOD OF TREATMENT OF LIVER DISEASE | HOWARD J. SMITH & ASSOCIATES PTY LTD (AU) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010130460-A1 | AMORPHOUS SILIBININ FOR THE TREATMENT OF VIRAL HEPATITIS | EUROMED S.A. (ES) | 2010-11-18 | — | — | WO | disclosed |
| EP-2219642-A1 | SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS | Madaus GmbH (DE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009062737-A1 | SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS | MADAUS GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108825-A1 | AMORPHOUS SILIBININ FOR THE TREATMENT OF VIRAL HEPATITIS | CSTB, PYGL, CCNB1 | MAPT 217/4885CYP2C9 1409/4885SLCO1B3 183/4885 |
| US-20130236420-A1 | SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS | VIP, STMN1, PYGL | MAPT 3465/4885CYP2C9 3034/4885SLCO1B3 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.